168 related articles for article (PubMed ID: 12183151)
1. Opportunities and obstacles in developing a vaccine for Entamoeba histolytica.
Miller-Sims VC; Petri WA
Curr Opin Immunol; 2002 Oct; 14(5):549-52. PubMed ID: 12183151
[TBL] [Abstract][Full Text] [Related]
2. The future for vaccine development against Entamoeba histolytica.
Quach J; St-Pierre J; Chadee K
Hum Vaccin Immunother; 2014; 10(6):1514-21. PubMed ID: 24504133
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the C-Terminal Fragment of Entamoeba histolytica Gal/GalNAc Lectin Intermediate Subunit as a Vaccine Candidate against Amebic Liver Abscess.
Min X; Feng M; Guan Y; Man S; Fu Y; Cheng X; Tachibana H
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004419. PubMed ID: 26824828
[TBL] [Abstract][Full Text] [Related]
4. Immunization with the Entamoeba histolytica surface metalloprotease EhMSP-1 protects hamsters from amebic liver abscess.
Roncolato EC; Teixeira JE; Barbosa JE; Zambelli Ramalho LN; Huston CD
Infect Immun; 2015 Feb; 83(2):713-20. PubMed ID: 25452550
[TBL] [Abstract][Full Text] [Related]
5. Intranasal immunization with Gal-inhibitable lectin plus an adjuvant of CpG oligodeoxynucleotides protects against Entamoeba histolytica challenge.
Ivory CP; Chadee K
Infect Immun; 2007 Oct; 75(10):4917-22. PubMed ID: 17620349
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a Gal-lectin subunit vaccine against experimental Entamoeba histolytica infection and colitis in baboons (Papio sp.).
Abd Alla MD; Wolf R; White GL; Kosanke SD; Cary D; Verweij JJ; Zhang MJ; Ravdin JI
Vaccine; 2012 Apr; 30(20):3068-75. PubMed ID: 22406457
[TBL] [Abstract][Full Text] [Related]
7. Progress towards development of a vaccine for amebiasis.
Stanley SL
Clin Microbiol Rev; 1997 Oct; 10(4):637-49. PubMed ID: 9336666
[TBL] [Abstract][Full Text] [Related]
8. Host-pathogen interaction in amebiasis and progress in vaccine development.
Huston CD; Petri WA
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):601-14. PubMed ID: 9832261
[TBL] [Abstract][Full Text] [Related]
9. Amoebiasis vaccine development: A snapshot on E. histolytica with emphasis on perspectives of Gal/GalNAc lectin.
Singh RS; Walia AK; Kanwar JR; Kennedy JF
Int J Biol Macromol; 2016 Oct; 91():258-68. PubMed ID: 27181579
[TBL] [Abstract][Full Text] [Related]
10. Identification of an epitope on the Entamoeba histolytica 170-kD lectin conferring antibody-mediated protection against invasive amebiasis.
Lotter H; Zhang T; Seydel KB; Stanley SL; Tannich E
J Exp Med; 1997 May; 185(10):1793-801. PubMed ID: 9151705
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the recombinant serine rich Entamoeba histolytica protein (SREHP) amebiasis vaccine in the African green monkey.
Stanley SL; Blanchard JL; Johnson N; Foster L; Kunz-Jenkins C; Zhang T; Tian K; Cogswell FB
Vaccine; 1995 Jul; 13(10):947-51. PubMed ID: 7483769
[TBL] [Abstract][Full Text] [Related]
12. Entamoeba histolytica: from adherence to enteropathy.
Ravdin JI
J Infect Dis; 1989 Mar; 159(3):420-9. PubMed ID: 2536786
[TBL] [Abstract][Full Text] [Related]
13. Antigenicity, immunogenicity and vaccine efficacy of the galactose-specific adherence protein of Entamoeba histolytica.
Ravdin JI; Shain DC; Kelsall BL
Vaccine; 1993; 11(2):241-6. PubMed ID: 8438621
[TBL] [Abstract][Full Text] [Related]
14. Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin.
Houpt E; Barroso L; Lockhart L; Wright R; Cramer C; Lyerly D; Petri WA
Vaccine; 2004 Jan; 22(5-6):611-7. PubMed ID: 14741152
[TBL] [Abstract][Full Text] [Related]
15. Adherence-blocking vaccine for amebiasis.
Petri WA; Chaudhry O; Haque R; Houpt E
Arch Med Res; 2006 Feb; 37(2):288-91. PubMed ID: 16380334
[TBL] [Abstract][Full Text] [Related]
16. Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.
Abhyankar MM; Noor Z; Tomai MA; Elvecrog J; Fox CB; Petri WA
Vaccine; 2017 Feb; 35(6):916-922. PubMed ID: 28089548
[TBL] [Abstract][Full Text] [Related]
17. Prospect for an Entamoeba histolytica Gal-lectin-based vaccine.
Gaucher D; Chadee K
Parasite Immunol; 2003 Feb; 25(2):55-8. PubMed ID: 12791100
[TBL] [Abstract][Full Text] [Related]
18. Protection in a gerbil model of amebiasis by oral immunization with Salmonella expressing the galactose/N-acetyl D-galactosamine inhibitable lectin of Entamoeba histolytica.
Mann BJ; Burkholder BV; Lockhart LA
Vaccine; 1997; 15(6-7):659-63. PubMed ID: 9178467
[TBL] [Abstract][Full Text] [Related]
19. Construction and immunogenicity of a codon-optimized Entamoeba histolytica Gal-lectin-based DNA vaccine.
Gaucher D; Chadee K
Vaccine; 2002 Sep; 20(27-28):3244-53. PubMed ID: 12213393
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the PE
Martínez-Hernández SL; Becerra-González VM; Muñoz-Ortega MH; Loera-Muro VM; Ávila-Blanco ME; Medina-Rosales MN; Ventura-Juárez J
J Immunol Res; 2021; 2021():6697900. PubMed ID: 33824880
[No Abstract] [Full Text] [Related]
[Next] [New Search]
